Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
February 02, 2016 12:00 AM

Pfizer earnings fall but top Wall Street 4Q forecasts

Associated Press
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Pfizer's fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations.

    The New York-based company's revenue rose by 7 percent, ending a long stretch of declining sales due to generic competition to one-time blockbusters. For the first time in five years, Pfizer posted higher revenue, excluding the impact of unfavorable exchange rates, as its 2015 sales rose 3 percent.

    In the latest quarter, Pfizer benefited from rising sales of its newer medicines, including its nascent portfolio of cancer drugs, as well as the addition of injectable medicines made by Hospira, which Pfizer acquired last September.

    The maker of Viagra and pain treatment Lyrica said on Tuesday that net income was $613 million, or 10 cents per share. A year earlier, its net income was $1.23 billion, or 19 cents per share.

    Adjusted for non-recurring costs, income in the latest quarter was 53 cents per share, a penny better than analysts expected. Pfizer also took an $806 million charge that basically wrote off its sales in Venezuela, where the bolivar's value has plunged to 1/32nd of its prior rate.

    Like many rival drugmakers, Pfizer lost patent protection over the last several years on many of its biggest drugs, led by cholesterol fighter Lipitor. It lost patent protection in November 2011 after nearly a decade as the world's top-selling drug. Altogether, new generic competition cost Pfizer $3.2 billion in 2015 and the company forecast it will lose another $2.3 billion to cheap copycats in 2016.

    In the fourth quarter, the drugmaker posted total revenue of $14.05 billion, up from $13.12 billion a year earlier. Analysts expected $13.61 billion.

    Pfizer said the strong dollar lowered its revenue by 7 percent. That's because its products are paid for in local currencies, reducing the value of the purchase price.

    "The good news is that sales of some of its key, innovative drug products continue to grow," noted analyst Erik Gordon, a professor at University of Michigan's Ross School of Business.

    Hospira's injectable medicines earned $1.51 billion, while sales of the Prevnar vaccine against pneumonia and other bacterial infections surged 43 percent to $1.86 billion, fueled by expanded approvals that cover many adults.

    Sales of Lyrica, for fibromyalgia and other pain, rose 6 percent in markets where its patent is still in force but worldwide fell 12 percent to $1.3 billion. Alliance revenue — mostly sales of clot-preventing drug Eliquis, which Pfizer markets with partner Bristol-Myers Squibb Co. — jumped 65 percent to $420 million.

    Altogether, Pfizer's innovative, or new drugs, segment had sales of $7.64 billion, up 15 percent. Its established products — ones that have lost patent protection or will soon — posted sales of $6.27 billion, down 2 percent.

    Pfizer is in the process of buying Irish drugmaker Allergan for $160 billion in a deal that would move Pfizer's official headquarters for tax purposes from New York to Allergan's base. The strategy, called a tax inversion, would sharply decrease Pfizer's income tax bill from its current U.S. tax rates, though the drugmaker's operations would still be run from New York.

    "One of the reasons for doing the Allergan deal was to ensure we had top-tier robust growth in our innovative business," Pfizer CEO Ian Read told analysts during a conference call.

    Pfizer said it expects full-year earnings in the range of $2.20 to $2.30 per share, with revenue in the range of $49 billion to $51 billion. The strong dollar is expected to cut the value of sales by $2.3 billion in 2016.

    During the year, Pfizer expects important data on some of its experimental drugs, particularly for cancer drugs that work by stimulating the immune system. Some are now being tested in combination with a second drug, and next year Pfizer will test some triple therapies, as researchers believe combo drugs will be more effective against many cancer types.

    For all of 2015, Pfizer reported net income of $7.75 billion, or $1.24 per share, and revenue of $48.9 billion.

    Pfizer shares slipped 10 cents to $30.07 in afternoon trading Tuesday. They are down 5 percent over the past year.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    GenesisCare files for Chapter 11 bankruptcy, seeks to offload U.S. operations
    GenesisCare files for Chapter 11 bankruptcy, seeks to offload U.S. operations
    bankruptcy 2
    Friday Health Plans shutting down amid financial shortfall
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing